Literature DB >> 29169082

The safety and efficacy of propofol as a replacement for amobarbital in intracarotid Wada testing of presurgical patients with epilepsy.

Kaci McCleary1, Joseph Barrash2, Mark Granner2, Kenneth Manzel2, Audrey Greider2, Robert Jones2.   

Abstract

OBJECTIVE: The intracarotid sodium amytal procedure (the "Wada test") has for many years been the gold standard for language and memory lateralization and remains an important part of presurgical analysis for patients with medically intractable seizures. Due to shortages in the key sedative (amobarbital), neuropsychologists have turned to alternatives such as propofol. Our aim was to investigate the safety and efficacy of propofol relative to amobarbital in the Wada test.
METHODS: We performed a retrospective review of the 97 Wada procedures performed at University of Iowa Hospitals and Clinics from 2007 through mid-2015.
RESULTS: Propofol produced similar lateralization rates as amobarbital for both language and memory. Similar rates of patients in each group went on to have the resection surgery. With regard to safety, there were no differences found in average rate or severity of adverse effects. None of the demographic characteristics reviewed were predictive of increased risk for either drug. SIGNIFICANCE: These findings support previous studies indicating that propofol is as safe and efficacious as amobarbital, and can continue to be used in Wada procedures with confidence.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adverse event; Anesthesia; Intractable epilepsy; Lateralization; Seizure

Mesh:

Substances:

Year:  2017        PMID: 29169082     DOI: 10.1016/j.yebeh.2017.10.037

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  1 in total

1.  Determination of language areas in patients with epilepsy using the super-selective Wada test.

Authors:  Kazuo Kakinuma; Shin-Ichiro Osawa; Hiroaki Hosokawa; Marie Oyafuso; Shoko Ota; Erena Kobayashi; Nobuko Kawakami; Kazushi Ukishiro; Kazutaka Jin; Makoto Ishida; Takafumi Sato; Mika Sakamoto; Kuniyasu Niizuma; Teiji Tominaga; Nobukazu Nakasato; Kyoko Suzuki
Journal:  IBRO Neurosci Rep       Date:  2022-08-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.